Business Description
InVivo Therapeutics Holdings Corp
NAICS : 325411
SIC : 2836
ISIN : US46186M4078
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.38 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 80.2 | |||||
3-Year EPS without NRI Growth Rate | 79.8 | |||||
3-Year FCF Growth Rate | 79.4 | |||||
3-Year Book Growth Rate | -70.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.06 | |||||
9-Day RSI | 40.82 | |||||
14-Day RSI | 40.3 | |||||
6-1 Month Momentum % | -45.6 | |||||
12-1 Month Momentum % | -70.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.3 | |||||
Quick Ratio | 14.3 | |||||
Cash Ratio | 12.88 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -379.5 | |||||
Shareholder Yield % | 28.34 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -77.97 | |||||
ROA % | -65.92 | |||||
ROIC % | -534.26 | |||||
ROC (Joel Greenblatt) % | -941 | |||||
ROCE % | -79.36 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.13 | |||||
Price-to-Tangible-Book | 0.13 | |||||
EV-to-EBIT | 0.75 | |||||
EV-to-EBITDA | 0.79 | |||||
EV-to-FCF | 0.73 | |||||
Price-to-Net-Current-Asset-Value | 0.13 | |||||
Price-to-Net-Cash | 0.15 | |||||
Earnings Yield (Greenblatt) % | 133.33 | |||||
FCF Yield % | -885.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
InVivo Therapeutics Holdings Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -3.078 | ||
Beta | 0 | ||
Volatility % | 71.02 | ||
14-Day RSI | 40.3 | ||
14-Day ATR (€) | 0.068596 | ||
20-Day SMA (€) | 0.35805 | ||
12-1 Month Momentum % | -70.36 | ||
52-Week Range (€) | 0.136 - 1.98 | ||
Shares Outstanding (Mil) | 3.11 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
InVivo Therapeutics Holdings Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
InVivo Therapeutics Holdings Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
InVivo Therapeutics Holdings Corp Frequently Asked Questions
What is InVivo Therapeutics Holdings Corp(FRA:04I)'s stock price today?
When is next earnings date of InVivo Therapeutics Holdings Corp(FRA:04I)?
Does InVivo Therapeutics Holdings Corp(FRA:04I) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |